Published in Biol Psychiatry on June 22, 2007
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry (2009) 1.44
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet (2009) 1.38
R9AP and R7BP: traffic cops for the RGS7 family in phototransduction and neuronal GPCR signaling. Trends Pharmacol Sci (2008) 1.30
Is the PANSS used correctly? a systematic review. BMC Psychiatry (2011) 1.22
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology (2010) 1.19
Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biol Psychiatry (2009) 1.09
Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells. Biol Psychiatry (2013) 1.05
Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull (2008) 1.02
Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophr Res (2008) 0.94
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin Neurosci (2009) 0.89
RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample. Schizophr Bull (2009) 0.82
Association of RGS4 variants with schizotypy and cognitive endophenotypes at the population level. Behav Brain Funct (2008) 0.81
Olanzapine Reversed Brain Gene Expression Changes Induced by Phencyclidine Treatment in Non-Human Primates. Mol Neuropsychiatry (2015) 0.76
Expression of the Longest RGS4 Splice Variant in the Prefrontal Cortex Is Associated with Single Nucleotide Polymorphisms in Schizophrenia Patients. Front Psychiatry (2016) 0.76
The silver lining of recent effectiveness trials. World Psychiatry (2009) 0.75
Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. J Mark Access Health Policy (2015) 0.75
Imaging Brain Development: Benefiting from Individual Variability. J Exp Neurosci (2015) 0.75
Genetic variation in the 3'-untranslated region of PAK1 influences schizophrenia susceptibility. Exp Ther Med (2017) 0.75
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
The International HapMap Project. Nature (2003) 73.65
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
The structure of haplotype blocks in the human genome. Science (2002) 50.88
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Models for longitudinal data: a generalized estimating equation approach. Biometrics (1988) 27.90
Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet (2001) 22.07
Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry (2003) 10.44
Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal (1999) 9.80
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry (2005) 9.23
Problems of reporting genetic associations with complex outcomes. Lancet (2003) 8.11
Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet (2003) 6.63
GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem (2000) 5.84
Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science (2000) 4.42
Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 4.15
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. Am J Hum Genet (2001) 3.73
Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet (2005) 3.03
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol (2002) 2.56
Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry (2001) 1.94
Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience (1991) 1.74
Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet (2002) 1.68
RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci (2006) 1.58
An update on the genetics of schizophrenia. Curr Opin Psychiatry (2006) 1.46
Commentary: grading the credibility of molecular evidence for complex diseases. Int J Epidemiol (2006) 1.23
The anatomy of dopamine in monkey and human prefrontal cortex. J Neural Transm Suppl (1992) 1.23
Confirming RGS4 as a susceptibility gene for schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2004) 1.22
Effect of population stratification on case-control association studies. I. Elevation in false positive rates and comparison to confounding risk ratios (a simulation study). Hum Hered (2004) 1.20
Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. Proc Natl Acad Sci U S A (1989) 1.15
Regional alterations in RGS4 protein in schizophrenia. Synapse (2006) 1.15
Genetic case-control association studies in neuropsychiatry. Arch Gen Psychiatry (2001) 1.11
NCAM1 and neurocognition in schizophrenia. Biol Psychiatry (2006) 1.10
Support for RGS4 as a susceptibility gene for schizophrenia. Biol Psychiatry (2004) 1.10
Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. Mol Psychiatry (2005) 1.06
Regulator of G-protein signaling 4 (RGS4) gene is associated with schizophrenia in Irish high density families. Am J Med Genet B Neuropsychiatr Genet (2004) 1.03
Regional expression of RGS4 mRNA in human brain. Eur J Neurosci (2004) 1.01
Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples. Biol Psychiatry (2006) 1.00
Effect of population stratification on case-control association studies. II. False-positive rates and their limiting behavior as number of subpopulations increases. Hum Hered (2004) 0.97
Failure to confirm genetic association between schizophrenia and markers on chromosome 1q23.3 in the region of the gene encoding the regulator of G-protein signaling 4 protein (RGS4). Am J Med Genet B Neuropsychiatr Genet (2006) 0.92
Association analysis of the RGS4 gene in Han Chinese and Scottish populations with schizophrenia. Genes Brain Behav (2005) 0.91
Bacterial artificial chromosome transgenic analysis of dynamic expression patterns of regulator of G-protein signaling 4 during development. I. Cerebral cortex. Neuroscience (2006) 0.89
Distribution of muscarinic receptor subtypes within architectonic subregions of the primate cerebral cortex. J Comp Neurol (1988) 0.89
Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians. Am J Med Genet B Neuropsychiatr Genet (2005) 0.85
D-2 dopamine receptors in the frontal cortex of rat and human. Life Sci (1985) 0.82
Evaluation of RGS4 as a candidate gene for schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2006) 0.81
Bacterial artificial chromosome transgenic analysis of dynamic expression patterns of regulator of G-protein signaling 4 during development. II. Subcortical regions. Neuroscience (2006) 0.80
Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain. J Chem Neuroanat (2002) 0.79
RGS4 genotype is not associated with antipsychotic medication response in schizophrenia. J Neural Transm (Vienna) (2006) 0.79
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature (2009) 33.26
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet (2007) 13.76
Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet (2009) 12.96
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol (2007) 6.96
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2012) 6.34
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet (2012) 5.78
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry (2009) 4.74
Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci (2002) 4.36
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Exome sequencing and the genetic basis of complex traits. Nat Genet (2012) 4.11
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
The Swedish Twin Registry in the third millennium: an update. Twin Res Hum Genet (2006) 3.58
A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A (2006) 3.55
Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet (2012) 3.50
Genome-wide association study of alcohol dependence. Arch Gen Psychiatry (2009) 3.08
Prevalence, heritability, and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry (2006) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence. Psychol Med (2004) 2.98
Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis (2008) 2.88
Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. Eur J Hum Genet (2008) 2.75
Recurrence risks for schizophrenia in a Swedish national cohort. Psychol Med (2006) 2.75
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
A transient placental source of serotonin for the fetal forebrain. Nature (2011) 2.71
Serotonin modulates the response of embryonic thalamocortical axons to netrin-1. Nat Neurosci (2007) 2.70
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci (2011) 2.61
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol (2007) 2.60
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet (2012) 2.50
Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics (2010) 2.45
Barriers to employment for people with schizophrenia. Am J Psychiatry (2006) 2.42
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Prenatal exposure to drugs: effects on brain development and implications for policy and education. Nat Rev Neurosci (2009) 2.33
Genome-wide association study implicates chromosome 9q21.31 as a susceptibility locus for asthma in mexican children. PLoS Genet (2009) 2.27
The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. Br J Psychiatry (2006) 2.24
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci (2003) 2.18
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry (2011) 2.15
Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry (2007) 2.12
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genet (2013) 2.08
Evidence of soil nutrient availability as the proximate constraint on growth of treeline trees in northwest Alaska. Ecology (2015) 2.05
False discoveries and models for gene discovery. Trends Genet (2003) 2.03
Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann Neurol (2007) 2.02
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Implications for the neural basis of social cognition for the study of schizophrenia. Am J Psychiatry (2003) 1.98
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics (2013) 1.97
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
How the timing and quality of early experiences influence the development of brain architecture. Child Dev (2010) 1.87
zCall: a rare variant caller for array-based genotyping: genetics and population analysis. Bioinformatics (2012) 1.87
Genome-wide association study of suicide attempts in mood disorder patients. Am J Psychiatry (2010) 1.85
Meta-analysis of genome-wide association studies with overlapping subjects. Am J Hum Genet (2009) 1.83
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry (2010) 1.82
Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci (2002) 1.79
Simulating association studies: a data-based resampling method for candidate regions or whole genome scans. Bioinformatics (2007) 1.77
Early experience modifies the postnatal assembly of autonomic emotional motor circuits in rats. J Neurosci (2005) 1.76
The organization of the transcriptional network in specific neuronal classes. Mol Syst Biol (2009) 1.74
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
seeQTL: a searchable database for human eQTLs. Bioinformatics (2011) 1.72
Studying gene and gene-environment effects of uncommon and common variants on continuous traits: a marker-set approach using gene-trait similarity regression. Am J Hum Genet (2011) 1.71
The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. Am Psychol (2005) 1.71
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry (2009) 1.70
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet (2002) 1.68
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry (2012) 1.67
Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry (2006) 1.66
Estimation of SNP heritability from dense genotype data. Am J Hum Genet (2013) 1.64
Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res (2008) 1.61
Integration of neuronal clones in the radial cortical columns by EphA and ephrin-A signalling. Nature (2009) 1.59
RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci (2006) 1.58
TAMAL: an integrated approach to choosing SNPs for genetic studies of human complex traits. Bioinformatics (2006) 1.57
Irritable bowel syndrome: a co-twin control analysis. Am J Gastroenterol (2007) 1.56
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry (2007) 1.56
Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. Autism Res (2012) 1.55
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Chronic widespread pain and its comorbidities: a population-based study. Arch Intern Med (2006) 1.49
Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract (2006) 1.48
Cigarettes and oral snuff use in Sweden: Prevalence and transitions. Addiction (2006) 1.48
Extensions to the modeling of initiation and progression: applications to substance use and abuse. Behav Genet (2006) 1.48
Population structure, migration, and diversifying selection in the Netherlands. Eur J Hum Genet (2013) 1.47
Medical and psychiatric morbidity in obese women with and without binge eating. Int J Eat Disord (2002) 1.46